Challenge / Opportunity
A Nepal-based pharmaceutical manufacturer with one of the country's most advanced WHO-GMP certified facility designed to EU-GMP standards and producing more than 70 pharmaceutical products, faced significant accumulated losses, an impaired balance sheet, and constrained access to growth capital. While the business possessed world-class manufacturing capabilities, experienced technical leadership, and substantial long-term growth potential, structural weaknesses in capital structure, governance, financial planning, and strategic execution limited its ability to realize enterprise value. The business required more than a financial turnaround: it required a comprehensive transformation to strengthen institutional foundations, restore investor confidence, and position itself for sustainable growth.
Royal Capital was initially engaged to undertake an independent diagnostic study, enterprise valuation, and strategic assessment. Based on the assessment, the engagement evolved into a long-term turnaround partnership encompassing corporate restructuring, executive advisory, operational improvement, and capital-raising support.
Our Approach
Following a comprehensive business diagnostic, we identified the underlying drivers of financial underperformance and assessed the company's long-term growth potential. These insights formed the basis of a multi-year institutional development roadmap focused on strengthening financial resilience, institutional governance, organizational effectiveness, and execution excellence.
The engagement extended well beyond a traditional advisory mandate. Working alongside the Board and executive leadership, we provided hands-on strategic and execution support across business planning, financial management, governance, organizational restructuring, and executive decision-making. In parallel, we enhanced the company's investment readiness through capital structure optimization, integrated financial modelling, investor communications, and IPO preparation.
The Impact
The engagement repositioned the business for its next phase of growth by strengthening governance, improving financial discipline, institutionalizing strategic planning & execution, and enhancing investment readiness.
Today, the company is executing a disciplined growth strategy supported by a world-class manufacturing platform, stronger corporate governance, and institutional-quality financial planning. With a strengthened operating framework and a clear pathway toward IPO readiness, the business is well positioned to expand its presence in domestic and international markets, attract long-term investment, and deliver sustainable value creation for all stakeholders.
Schedule a Meeting